Antibacterial agents specifically inhibiting lipopolysaccharide synthesis

Area of Science:

• Microbiology
• Drug Discovery
• Biochemistry

Background:

• Antibiotic resistance in Gram-negative bacteria necessitates novel antibacterial agents.
• Lipopolysaccharide (LPS) biosynthesis is unique to Gram-negative bacteria and essential for their survival and virulence.
• Existing antibacterial strategies have not successfully targeted LPS synthesis.

Purpose of the Study:

• To design and validate the first antibacterial compound that specifically inhibits lipopolysaccharide (LPS) synthesis.
• To identify and target the enzyme 3-deoxy-D-manno-octulosonate cytidylytransferase (CMP-KDO synthetase) as a novel antibacterial strategy.

Main Methods:

• Purification and study of CMP-KDO synthetase enzyme.
• Design of a specific inhibitor targeting CMP-KDO synthetase.
• Utilizing a peptide carrier for intracellular delivery of the inhibitor.
• Assessing the effects of the inhibitor on LPS synthesis, growth, and outer membrane integrity.

Main Results:

• The designed inhibitor specifically targets and inhibits CMP-KDO synthetase.
• Inhibition of CMP-KDO synthetase led to cessation of LPS synthesis and accumulation of lipid A precursor.
• The compound caused growth stasis and compromised outer membrane structure and function in Gram-negative bacteria.
• Effective antibacterial action depended on the oligopeptide permease system and intracellular aminopeptidase activity.

Conclusions:

• A novel class of antibacterial compounds targeting LPS synthesis has been successfully designed.
• Inhibition of CMP-KDO synthetase represents a promising strategy for combating Gram-negative bacterial infections.
• The prodrug approach with peptide carriers demonstrates effective intracellular delivery and targeted inhibition.